Skip to content

Extramedullary disease in MM associated with severe toxicities following BCMA-targeted CAR T-cell therapy
Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL
Dr. Sundar Jagannath defines ‘cure’ in multiple myeloma
FDA adds enterocolitis risk warning to approved CAR-T cell therapy
Tara Graff, MD, talks community care and the CAR-T vs bispecific debate

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL

Cellular Therapy

Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL

Leukemia

Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL

Lymphoma

Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL

Multiple Myeloma

Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL

Myelodysplastic Syndromes

Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

December 3, 2025

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Meetings / Conferences SOHO 2025 Leukemia News

Leukemia

Leukemia News SOHO 2025 News Video Interviews

Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL

by SOHO Insider Editors
December 1, 2025
0 Comments

Leukemia News

FDA approves ziftomenib for relapsed or refractory NMP1-mutated AML

by Leah Sherwood
November 14, 2025
0 Comments

Leukemia News SOHO 2025

Dr. Jabbour discusses investigational menin inhibitor bleximenib

by Leah Sherwood
November 3, 2025
0 Comments

Person stepping on a scale

Leukemia News SOHO 2025 Leukemia Chronic Lymphocytic Leukemia

Obesity increases infection risk in CLL for patients treated with a BTKi

by Leah Sherwood
October 31, 2025
0 Comments

Leukemia News SOHO 2025 News Video Interviews

How does MRD guide treatment decisions in ALL?

by SOHO Insider Editors
October 28, 2025
0 Comments

Leukemia News SOHO 2025 Educational Resources Acute Myeloid Leukemia Meetings / Conferences News

Future Role of CPX-351 and CPX-351-Based Combinations

by SOHO Insider Editors
October 15, 2025
0 Comments

Drs. Short and Kantarjian

Leukemia News SOHO 2025 Leukemia Acute Lymphoblastic Leukemia Meetings / Conferences Video Interviews

Can sequencing chemotherapy and immunotherapy transform ALL treatment?

by Leah Sherwood
October 13, 2025
0 Comments

Short & Kantarjian

Leukemia News SOHO 2025 Meetings / Conferences News Video Interviews

Drs. Kantarjian and Short detail ALL treatment shift at SOHO 2025

by Leah Sherwood
October 13, 2025
0 Comments

SOHO Insider

Leukemia News SOHO 2025

Drs. Kantarjian and Mauro discuss ELVN-001 in CML

by SOHO Insider Editors
October 10, 2025
0 Comments

Doctor holding an ipad

Leukemia News SOHO 2025

Early-phase CLL trial shows bexobrutideg well tolerated

by Leah Sherwood
October 3, 2025
0 Comments

1
2

Top Categories

Cellular Therapy

13

Leukemia

68

Lymphoma

63

Multiple Myeloma

59

Myelodysplastic Syndromes

24

Myeloproliferative Neoplasms

12

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Early-phase CLL trial shows bexobrutideg well tolerated

Cellular Therapy

Early-phase CLL trial shows bexobrutideg well tolerated

Leukemia

Early-phase CLL trial shows bexobrutideg well tolerated

Lymphoma

Early-phase CLL trial shows bexobrutideg well tolerated

Multiple Myeloma

Early-phase CLL trial shows bexobrutideg well tolerated

Myelodysplastic Syndromes

Early-phase CLL trial shows bexobrutideg well tolerated

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Extramedullary disease in MM associated with severe toxicities following BCMA-targeted CAR T-cell therapy

Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL

up close shot of a doctor

Dr. Sundar Jagannath defines ‘cure’ in multiple myeloma

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.